RUBY-3 is being conducted to determine if a new investigational drug, povetacicept, is safe and potentially beneficial for people with anti-neutrophil cytoplasmic antibody associated vasculitis.
Investigational means that povetacicept is still being evaluated and is not approved by health authority (e.g., the United States Food and Drug Administration (FDA)) for anti-neutrophil cytoplasmic antibody associated vasculitis or another condition.
Additional information is available at RUBY-3 ClinicalTrials.gov.